ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer

Overview of attention for article published in Frontiers in immunology, August 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 8 X users

Citations

dimensions_citation: 43 Dimensions

Readers on

mendeley: 37 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 35,053 followers.

RT @4baseCare: ARID1A, ARID1B, and ARID2 mutations contribute to high MSI & TMB, elevated expression of PD-L1, and modulate the immune micr…

08 Nov 2022

Reply Repost Favourite

RT @4baseCare: ARID1A, ARID1B, and ARID2 mutations contribute to high MSI & TMB, elevated expression of PD-L1, and modulate the immune micr…

08 Nov 2022

Reply Repost Favourite

ARID1A, ARID1B, and ARID2 mutations contribute to high MSI & TMB, elevated expression of PD-L1, and modulate the immune microenvironment, thereby serving as a predictive biomarker for Immune Checkpoint Blockade (ICB) in NSCLC patients. LINK: https://t

08 Nov 2022

Reply Repost Favourite

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With ... https://t.co/seudDsbezI

27 Nov 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.